Simulations Plus, Inc. (SLP)

$30.26

-1.57

(-4.93%)▲

Live

Performance

  • $29.96
    $31.93
    $30.26
    downward going graph

    1.01%

    Downside

    Day's Volatility :6.19%

    Upside

    5.23%

    downward going graph
  • $27.22
    $51.22
    $30.26
    downward going graph

    10.05%

    Downside

    52 Weeks Volatility :46.86%

    Upside

    40.92%

    downward going graph

Returns

PeriodSimulations Plus, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-11.31%
-3.2%
0.0%
6 Months
-35.64%
1.9%
0.0%
1 Year
-17.11%
14.8%
0.0%
3 Years
-42.46%
9.7%
-26.7%

Highlights

Market Capitalization
640.7M
Book Value
$9.10
Dividend Share
0.24
Dividend Yield
0.75%
Earnings Per Share (EPS)
0.49
PE Ratio
65.16
PEG Ratio
9.77
Wall Street Target Price
52.75
Profit Margin
14.22%
Operating Margin TTM
7.76%
Return On Assets TTM
2.85%
Return On Equity TTM
5.65%
Revenue TTM
70.0M
Revenue Per Share TTM
3.5
Quarterly Revenue Growth YOY
19.400000000000002%
Gross Profit TTM
43.1M
EBITDA
12.3M
Diluted Eps TTM
0.49
Quarterly Earnings Growth YOY
0.48
EPS Estimate Current Year
0.48
EPS Estimate Next Year
0.63
EPS Estimate Current Quarter
0.03
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Simulations Plus, Inc.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 74.32%

Current $30.26
Target $52.75

Company Financials

FY19Y/Y Change
Revenue
34.0M
↑ 14.51%
Net Income
8.6M
↓ 3.93%
Net Profit Margin
25.27%
↓ 4.85%
FY20Y/Y Change
Revenue
41.6M
↑ 22.43%
Net Income
9.3M
↑ 8.72%
Net Profit Margin
22.44%
↓ 2.83%
FY21Y/Y Change
Revenue
46.5M
↑ 11.73%
Net Income
9.8M
↑ 4.82%
Net Profit Margin
21.05%
↓ 1.39%
FY22Y/Y Change
Revenue
53.9M
↑ 16.01%
Net Income
12.5M
↑ 27.61%
Net Profit Margin
23.16%
↑ 2.11%
FY23Y/Y Change
Revenue
59.6M
↑ 10.52%
Net Income
10.0M
↓ 20.2%
Net Profit Margin
16.72%
↓ 6.44%
FY24Y/Y Change
Revenue
70.0M
↑ 17.52%
Net Income
10.0M
↓ 0.07%
Net Profit Margin
14.22%
↓ 2.5%
Q2 FY23Q/Q Change
Revenue
16.2M
↑ 3.07%
Net Income
4.0M
↓ 3.98%
Net Profit Margin
24.69%
↓ 1.81%
Q3 FY23Q/Q Change
Revenue
15.6M
↓ 3.73%
Net Income
534.0K
↓ 86.68%
Net Profit Margin
3.42%
↓ 21.27%
Q4 FY23Q/Q Change
Revenue
14.5M
↓ 7.22%
Net Income
1.9M
↑ 264.23%
Net Profit Margin
13.41%
↑ 9.99%
Q1 FY24Q/Q Change
Revenue
18.3M
↑ 26.24%
Net Income
4.0M
↑ 107.15%
Net Profit Margin
22.01%
↑ 8.6%
Q2 FY24Q/Q Change
Revenue
18.5M
↑ 1.31%
Net Income
3.1M
↓ 22.14%
Net Profit Margin
16.92%
↓ 5.09%
Q3 FY24Q/Q Change
Revenue
18.7M
↑ 0.84%
Net Income
800.0K
↓ 74.5%
Net Profit Margin
4.28%
↓ 12.64%
FY19Y/Y Change
Total Assets
45.2M
↑ 4.43%
Total Liabilities
7.5M
↓ 33.82%
FY20Y/Y Change
Total Assets
168.4M
↑ 272.64%
Total Liabilities
12.4M
↑ 64.81%
FY21Y/Y Change
Total Assets
180.0M
↑ 6.86%
Total Liabilities
14.2M
↑ 14.62%
FY22Y/Y Change
Total Assets
188.4M
↑ 4.67%
Total Liabilities
10.1M
↓ 28.61%
FY23Y/Y Change
Total Assets
186.1M
↓ 1.21%
Total Liabilities
16.1M
↑ 58.59%
FY24Y/Y Change
Total Assets
196.6M
↑ 5.66%
Total Liabilities
14.2M
↓ 11.6%
Q2 FY23Q/Q Change
Total Assets
179.1M
↑ 3.43%
Total Liabilities
9.7M
↑ 13.2%
Q3 FY23Q/Q Change
Total Assets
186.1M
↑ 3.89%
Total Liabilities
16.1M
↑ 64.94%
Q4 FY23Q/Q Change
Total Assets
185.8M
↓ 0.17%
Total Liabilities
13.4M
↓ 16.39%
Q1 FY24Q/Q Change
Total Assets
194.0M
↑ 4.41%
Total Liabilities
16.9M
↑ 26.03%
Q2 FY24Q/Q Change
Total Assets
192.7M
↓ 0.66%
Total Liabilities
11.8M
↓ 30.13%
Q3 FY24Q/Q Change
Total Assets
196.6M
↑ 2.05%
Total Liabilities
14.2M
↑ 20.08%
FY19Y/Y Change
Operating Cash Flow
11.6M
↑ 25.32%
Investing Cash Flow
-2.0M
↓ 16.02%
Financing Cash Flow
-7.6M
↑ 102.67%
FY20Y/Y Change
Operating Cash Flow
10.9M
↓ 6.24%
Investing Cash Flow
-75.5M
↑ 3760.72%
Financing Cash Flow
102.4M
↓ 1438.48%
FY21Y/Y Change
Operating Cash Flow
19.2M
↑ 75.98%
Investing Cash Flow
-26.7M
↓ 64.58%
Financing Cash Flow
-4.7M
↓ 104.58%
FY22Y/Y Change
Operating Cash Flow
17.9M
↓ 6.79%
Investing Cash Flow
4.3M
↓ 116.1%
Financing Cash Flow
-7.6M
↑ 62.72%
Q2 FY23Q/Q Change
Operating Cash Flow
8.5M
↑ 54.27%
Investing Cash Flow
7.9M
↑ 48.05%
Financing Cash Flow
-628.0K
↓ 97.01%

Technicals Summary

Sell

Neutral

Buy

Simulations Plus, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Simulations Plus, Inc.
Simulations Plus, Inc.
0.35%
-35.64%
-17.11%
-42.46%
-8.01%
Solventum Corp
Solventum Corp
0.94%
7.59%
1.36%
1.36%
1.36%
Doximity, Inc.
Doximity, Inc.
25.98%
124.84%
108.11%
-25.31%
-0.26%
Veeva Systems Inc.
Veeva Systems Inc.
10.82%
14.41%
34.44%
-26.1%
56.83%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-8.12%
4.55%
16.58%
39.16%
39.16%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Simulations Plus, Inc.
Simulations Plus, Inc.
65.16
65.16
9.77
0.48
0.06
0.03
0.01
9.1
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Doximity, Inc.
Doximity, Inc.
66.72
66.72
2.42
0.9
0.19
0.12
NA
5.15
Veeva Systems Inc.
Veeva Systems Inc.
63.24
63.24
1.36
4.76
0.13
0.06
NA
32.04
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
23.27
23.27
2.12
4.3
0.22
0.06
0.0
18.2
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Simulations Plus, Inc.
Simulations Plus, Inc.
Buy
$640.7M
-8.01%
65.16
14.22%
Solventum Corp
Solventum Corp
Hold
$10.8B
1.36%
NA
15.73%
Doximity, Inc.
Doximity, Inc.
Hold
$10.8B
-0.26%
66.72
33.69%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$38.3B
56.83%
63.24
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$38.8B
39.16%
23.27
8.56%

Insights on Simulations Plus, Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 14.5M → 18.7M (in $), with an average increase of 7.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 4.02M → 800.0K (in $), with an average decrease of 48.3% per quarter

  • Vs DOCS

    In the last 1 year, Doximity, Inc. has given 108.1% return, outperforming this stock by 125.2%

  • Vs VEEV

    In the last 3 years, Simulations Plus, Inc. has experienced a drawdown of -43.6%, however Veeva Systems Inc. resisted the overall trend and outperformed by 15.5%

Institutional Holdings

  • BlackRock Inc

    12.28%

  • Conestoga Capital Advisors, LLC

    9.65%

  • Neuberger Berman Group LLC

    6.34%

  • Vanguard Group Inc

    5.75%

  • Ranger Investment Management LP

    4.49%

  • Morgan Stanley - Brokerage Accounts

    3.99%

Company Information

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res

Organization
Simulations Plus, Inc.
Employees
243
CEO
Dr. Walter S. Woltosz M.A.S., M.S.
Industry
Technology Services

FAQs